| Edoxaban versus warfarin in patients with atrial fibrillation RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ... New England Journal of Medicine 369 (22), 2093-2104, 2013 | 6166 | 2013 |
| Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials CT Ruff, RP Giugliano, E Braunwald, EB Hoffman, N Deenadayalu, ... The Lancet 383 (9921), 955-962, 2014 | 5974 | 2014 |
| COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review B Bikdeli, MV Madhavan, D Jimenez, T Chuich, I Dreyfus, E Driggin, ... Journal of the American college of cardiology 75 (23), 2950-2973, 2020 | 3514 | 2020 |
| Oral apixaban for the treatment of acute venous thromboembolism G Agnelli, HR Buller, A Cohen, M Curto, AS Gallus, M Johnson, ... New England Journal of Medicine 369 (9), 799-808, 2013 | 2899 | 2013 |
| Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer PS Wells, DR Anderson, M Rodger, JS Ginsberg, C Kearon, M Gent, ... Thrombosis and haemostasis 83 (03), 416-420, 2000 | 2450 | 2000 |
| Low-molecular-weight heparins JI Weitz New England Journal of Medicine 337 (10), 688-698, 1997 | 2178 | 1997 |
| Idarucizumab for dabigatran reversal CV Pollack Jr, PA Reilly, J Eikelboom, S Glund, P Verhamme, ... New England Journal of Medicine 373 (6), 511-520, 2015 | 2085 | 2015 |
| Thrombosis: a major contributor to global disease burden GE Raskob, P Angchaisuksiri, AN Blanco, H Buller, A Gallus, BJ Hunt, ... Arteriosclerosis, thrombosis, and vascular biology 34 (11), 2363-2371, 2014 | 1801 | 2014 |
| Edoxaban for the treatment of cancer-associated venous thromboembolism GE Raskob, N Van Es, P Verhamme, M Carrier, M Di Nisio, D Garcia, ... New England Journal of Medicine 378 (7), 615-624, 2018 | 1766 | 2018 |
| Hematology E-Book: Basic Principles and Practice R Hoffman, EJ Benz, LE Silberstein, H Heslop, J Weitz, ME Salama Elsevier Health Sciences, 2022 | 1754 | 2022 |
| Apixaban for extended treatment of venous thromboembolism G Agnelli, HR Buller, A Cohen, M Curto, AS Gallus, M Johnson, A Porcari, ... New England Journal of Medicine 368 (8), 699-708, 2013 | 1746 | 2013 |
| Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events JW Eikelboom, J Hirsh, JI Weitz, M Johnston, Q Yi, S Yusuf Circulation 105 (14), 1650-1655, 2002 | 1666 | 2002 |
| A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis M Levine, M Gent, J Hirsh, J Leclerc, D Anderson, J Weitz, J Ginsberg, ... New England Journal of Medicine 334 (11), 677-681, 1996 | 1650 | 1996 |
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism C Kearon, M Gent, J Hirsh, J Weitz, MJ Kovacs, DR Anderson, AG Turpie, ... New England Journal of Medicine 340 (12), 901-907, 1999 | 1510 | 1999 |
| Use of a clinical model for safe management of patients with suspected pulmonary embolism PS Wells, JS Ginsberg, DR Anderson, C Kearon, M Gent, AG Turpie, ... Annals of internal medicine 129 (12), 997-1005, 1998 | 1492 | 1998 |
| Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. JI Weitz, M Hudoba, D Massel, J Maraganore, J Hirsh The Journal of clinical investigation 86 (2), 385-391, 1990 | 1470 | 1990 |
| Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review JI Weitz, J Byrne, GP Clagett, ME Farkouh, JM Porter, DL Sackett, ... Circulation 94 (11), 3026-3049, 1996 | 1332 | 1996 |
| Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines DA Garcia, TP Baglin, JI Weitz, MM Samama Chest 141 (2), e24S-e43S, 2012 | 1303 | 2012 |
| Idarucizumab for dabigatran reversal—full cohort analysis CV Pollack Jr, PA Reilly, J Van Ryn, JW Eikelboom, S Glund, ... New England Journal of Medicine 377 (5), 431-441, 2017 | 1286 | 2017 |
| Accuracy of clinical assessment of deep-vein thrombosis PS Wells, J Hirsh, DR Anderson, AWA Lensing, G Foster, C Kearon, ... The Lancet 345 (8961), 1326-1330, 1995 | 1137 | 1995 |
Jack HirshEmeritus professor of medicine Mcmaster University Hamilton Ontario canada確認したメール アドレス: mcmaster.ca
